SEGMENT INFORMATION (Details) $ in Thousands |
3 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|
|
Jun. 30, 2020
USD ($)
|
Jun. 30, 2019
USD ($)
|
Jun. 30, 2020
USD ($)
segment
|
Jun. 30, 2019
USD ($)
|
Dec. 31, 2019
USD ($)
|
|
| Segment Reporting Information [Line Items] | |||||
| Number of operating segments | segment | 2 | ||||
| Product sales, net | $ 5,396 | $ 16,854 | $ 13,666 | $ 31,765 | |
| Gross profit | 2,322 | 11,951 | 6,330 | 22,510 | |
| Research and development | 746 | 1,688 | 2,255 | 3,030 | |
| Selling, general and administrative | 6,233 | 9,009 | 14,052 | 27,604 | |
| Operating income (loss) | (4,657) | 1,254 | (9,977) | (8,124) | |
| Goodwill | 2,788 | 2,788 | $ 2,788 | ||
| Intangible assets | 3,748 | 3,748 | 3,766 | ||
| Consumer Products Segment | |||||
| Segment Reporting Information [Line Items] | |||||
| Product sales, net | 5,396 | 16,854 | 13,666 | 31,765 | |
| Gross profit | 2,322 | 11,951 | 6,330 | 22,510 | |
| Research and development | 152 | 679 | 457 | 1,378 | |
| Selling, general and administrative | 6,180 | 8,999 | 13,990 | 27,584 | |
| Operating income (loss) | (4,010) | 2,273 | (8,117) | (6,452) | |
| Specialty Pharmaceutical Segment | |||||
| Segment Reporting Information [Line Items] | |||||
| Product sales, net | 0 | 0 | 0 | 0 | |
| Gross profit | 0 | 0 | 0 | 0 | |
| Research and development | 594 | 1,009 | 1,798 | 1,652 | |
| Selling, general and administrative | 53 | 10 | 62 | 20 | |
| Operating income (loss) | (647) | $ (1,019) | (1,860) | $ (1,672) | |
| Goodwill | 2,800 | 2,800 | 2,800 | ||
| Intangible assets | $ 3,700 | $ 3,700 | $ 3,800 | ||
| X | ||||||||||
- Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|